-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $44

Benzinga·02/25/2026 19:15:45
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $45 to $44.